Discover what makes HBKU an innovation-based entrepreneurial university.
Meet the leadership making HBKU a transformative place to study and work.
Read about the people who create a unique environment for learning and research.
Join an innovative organization and the people who are shaping tomorrow.
Dr Al-Ejeh’s team at QBRI investigates new diagnostics and therapeutics approaches for aggressive types of cancer to improves outcomes, particularly groups of breast cancer patients who do not benefit from the current treatments. The research aims to bridge translational and discovery research and clinical research and practice.
This research team at the Translational Cancer Research Group ( TCRG ) integrates two sub-themes: Clinical Research and Preclinical Research. The team deploys an interdisciplinary approach with a diversity of methods and techniques to achieve both immediate and long-term strategic objectives. The team's approach relies heavily on strong collaborations with oncologists and pathologists.
Clinical Research (objectives 1-4): Develop multi-marker diagnostics based on multi-omics from different sources, including the published Cancer Genome Atlas (TCGA) data and data generated from Qatar using retrospective and prospective samples. The research is conducted in collaboration with clinicians and pathologists to build the Qatar BRCA TMAs - Qatar Breast Cancer tissue microarrays.
Preclinical Research (objectives 5-7): Develop preclinical models from patient tumors at the Qatar BRCA Cell Bank . Investigate novel biomarkers to characterize their function in driving cancer progression and their potential as new therapeutic targets.